Renerva Receives FDA Approval for First-in-Human Trial of Novel Nerve Capping Device to Prevent Chronic Amputation Pain
核心洞察
Renerva Inc (搜索) received FDA Investigational Device Exemption approval to begin first-in-human clinical trials of its PNM-CAP (搜索) nerve capping device at The Ohio State University Wexner Medical Center.
The device is designed to prevent neuroma (搜索) formation and chronic pain following nerve transection during amputation (搜索) procedures, addressing a critical unmet need for over 2 million US amputees.
Preclinical studies published in npj Regenerative Medicine demonstrated up to 16-fold reduction in nerve growth and 3.5-fold reduction in pain behavior compared to standard care controls.
Renerva Inc (搜索), a Pittsburgh-based medical device company, has received Investigational Device Exemption (IDE) approval from the US Food and Drug Administration to initiate a first-in-human clinical study for its PNM-CAP (搜索) nerve capping device. The milestone represents a significant advancement in addressing chronic neuropathic pain (搜索) following amputation (搜索), a debilitating condition affecting millions of patients worldwide.
The clinical trial will be conducted at The Ohio State University Wexner Medical Center under the leadership of Principal Investigator Amy M. Moore, MD, who holds the Robert L. Ruberg MD Alumni Endowed Chair of the Department of Plastic and Reconstructive Surgery. The study will assess PNM-CAP (搜索)'s ability to prevent neuroma (搜索) formation, chronic pain, and opioid dependence in amputation (搜索) patients.
Addressing a Critical Unmet Medical Need
The PNM-CAP (搜索) device targets a fundamental problem in amputation (搜索) surgery: the formation of neuromas following nerve transection. When nerves are cut during amputation procedures, the axons (搜索) inside can form disorganized nerve growth called neuromas, which make the nerve extremely sensitive and cause severe chronic pain. In the United States alone, there are over 2 million amputees, with 500,000 new amputations performed annually. Each amputation involves multiple transected nerves, multiplying the risk of neuroma (搜索) development.
"Chronic neuropathic pain (搜索) following amputation (搜索) is a debilitating condition that profoundly impacts my patients' lives, and our current treatment options are limited," said Dr. Moore. "The unique PNM-CAP (搜索) design addresses the underlying mechanisms of neuroma (搜索) formation, and we are eager to lead this clinical study to determine its potential impact and hopefully provide a meaningful solution for these patients."
Strong Preclinical Foundation
The FDA approval was supported by robust preclinical data recently published in npj Regenerative Medicine. The studies demonstrated that the Renerva technology has a profound impact on inhibiting nerve growth, a key event in neuroma (搜索) formation. According to Bryan Brown, chief technology officer of Renerva, "Our preclinical studies demonstrate that PNM-CAP (搜索) profoundly inhibits nerve growth and leads to a 3.5-fold reduction in average pain behavior observed over a four-month period compared to untreated controls."
The preclinical data showed up to a 16-fold reduction in nerve growth compared to standard-of-care controls, with the 3.5-fold reduction in average pain behavior observed over a four-month period representing a significant therapeutic advance.
Innovative Device Mechanism
The PNM-CAP (搜索) nerve cap is designed to limit axon growth following nerve transection. "Our nerve cap is designed to limit how far those axons (搜索) can grow," Brown explained. "As the cap degrades, it's replaced with healthy, natural connective tissue. We've found that this process stops the axons from becoming entangled, halts their growth, and prevents the formation of painful neuroma (搜索)."
This mechanism addresses the root cause of post-amputation (搜索) pain rather than merely treating symptoms, potentially offering a more effective long-term solution for patients.
Clinical Trial Design and Objectives
The first-in-human study will enroll patients undergoing nerve management procedures for intractable neuropathic pain. The clinical trial will test the nerve cap in 10 patients over the span of one year, with primary endpoints evaluating reduction in pain, reduction in opioid consumption, and overall improvement in quality of life.
The study represents a critical transition for Renerva from a preclinical to clinical-stage company. "Receiving IDE approval is a pivotal milestone for Renerva, transitioning us into a clinical-stage company and significantly de-risking our technology path," said Lorenzo Soletti, CEO of Renerva. "This achievement, which allows us to proceed with our first-in-human study, is a critical value inflection point for the company."
Development and Commercialization Path
Renerva's technology was jointly developed at the University of Pittsburgh and Cornell University, with early support from Pitt's Office of Innovation and Entrepreneurship helping to establish the scientific foundation and business strategy that led to Renerva's 2017 launch. The company plans to pursue US market clearance for the PNM-CAP (搜索) device once interim clinical data becomes available.
The partnership with The Ohio State University Wexner Medical Center, recognized as one of America's top-ranked academic medical centers, provides access to world-class expertise in peripheral nerve (搜索) injury and repair. The Department of Plastic and Reconstructive Surgery at Ohio State features the largest team of reconstructive microsurgeons in the Midwest, positioning the trial for success.